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The masking of clinically significant alloantibodies by warm 
autoantibodies presents challenges in pretransfusion testing. 
The adoption of transfusion practices such as the issuing of “least 
incompatible” red blood cells (RBCs) without a complete antibody 
workup is potentially unsafe for patients. Several autoadsorption 
methods can be used to remove autoantibody reactivity. ZZAP 
treatment of autologous RBCs is an efficient way to prepare the 
cells for autoadsorption. Autoadsorbed serum or plasma can then 
be used to remove autoantibody reactivity and identify clinically 
significant alloantibodies. Immunohematology 2018;34: 
1–3.
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Principle
Warm autoantibodies (WAAs) present serologic challenges 
in pretransfusion compatibility testing. These autoantibodies, 
which are optimally reactive at 37°C, may mask the presence 
of clinically significant alloantibodies by agglutinating most 
or all red blood cells (RBCs) tested. Studies have shown that 
the incidence of clinically significant alloantibodies is higher 
in patient sera containing WAAs than in multiply transfused 
patients without autoimmune hemolytic anemia (AIHA).1–4
Some blood banks have implemented the policy of 
transfusing “least incompatible” non-phenotypically matched 
RBCs, and others transfuse least incompatible RBCs that are 
phenotypically matched for either the full phenotype or only 
for the common antigens in the Rh blood group system and for 
K. The transfusion of least incompatible non-phenotypically 
matched units without exclusion of other alloantibodies 
poses a major risk to patients with WAAs because hemolysis 
secondary to undetected alloantibodies can be falsely 
attributed to an increasing severity of AIHA.2
The detection of clinically significant alloantibodies can 
be achieved through the removal of autoantibody from the 
patient’s plasma or serum. Autoantibody removal can be 
achieved by adsorbing the plasma or serum onto autologous 
RBCs (provided the patient has not been transfused in the 
last 3 months).5 Alternatively, if the patient has been recently 
transfused or autologous RBCs are limited, allogeneic RBC 
adsorption may be performed.5–7 Autologous adsorption is 
preferred because of the risk of adsorbing an alloantibody to a 
high-prevalence antigen onto allogeneic adsorbing RBCs.
Indications
To effectively achieve the autoadsorption of WAAs, 
initial preparation of the patient’s RBCs is required. In vivo 
adsorptions occur at 37°C, and all the antigen sites on the 
patient’s RBCs may be blocked with immunoglobulin.5 
Methods for immunoglobulin dissociation may include partial 
heat elution at 45°C, gentle heat elution at 56°C, treatment 
with proteolytic enzymes (papain and/or ficin), treatment with 
chloroquine diphosphate, or treatment with a ZZAP reagent 




• 0.2 M DTT
• 1% cysteine-activated 
papain or 1% ficin
• Isotonic saline
• Patient’s autologous RBCs
• 1-mL graduated pipettes
• 37°C water bath
• Large-bore test tubes
• Calibrated centrifuge
• Filter paper (optional)




• Mix 2 volumes of ZZAP and 1 volume of packed 
RBCs.
• Incubate mixture.
• Wash to remove ZZAP.
• Centrifuge to pack RBCs.
• Remove supernatant.
Adsorption
• Mix serum/plasma and ZZAP-treated packed 
RBCs.
• Incubate mixture.
• Centrifuge to pack RBCs.
• Harvest serum/plasma.
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Treatment of the adsorbing RBCs with ZZAP has been 
shown to be one of the most effective methods for pretreating 
adsorption RBCs. It simultaneously removes bound IgG and 
enhances autoantibody uptake during the adsorption process. 
In addition to removing IgG from coated RBCs, ZZAP also 
removes bound IgM and complement (approximately 35% of 
patients with WAAs present with cold autoantibodies reactive 
at room temperature).7,9
ZZAP will destroy some antigen sites on RBCs. Enzymes 
remove sialic acid from the RBCs and will destroy some 
antigens, including M, N, S, s, Fya, Fyb, Ena, Ge, JMH, Ch/
Rg, and Inb. DTT will alter Yta, JMH, Kna, McCa, Yka, LWa, 
and LWb, as well as all Kell, Lutheran, Dombrock, and Cromer 
blood group antigens. Alloantibodies and autoantibodies with 
a specificity to these altered antigens will remain in the plasma 
or serum after the adsorption process with ZZAP-treated 
RBCs.5,10–13
The number of adsorptions needed to adequately remove 
the autoantibody usually correlates with the strength of WAA 
reactivity against panel RBCs. In some instances, additional 
adsorptions may be necessary.5,7,10
Procedure
Preparation of ZZAP
Combine 0.5 mL of 1 percent cysteine-activated papain, 
2.5 mL of 0.2 M DTT, and 2 mL of pH 7.3 phosphate-buffered 
saline. In place of papain, 1 mL of 1 percent ficin can be 
combined with 2.5 mL of 0.2 M DTT and 1.5 mL of pH 7.3 
phosphate-buffered saline. If the enzyme used to make ZZAP is 
prepared in-house, the stock solution must have the reactivity 
and incubation time standardized by the in-house procedure 
after each preparation. If using a commercially prepared 
enzyme solution, follow the manufacturer’s directions.14–16
RBC Treatment
RBCs may be unwashed before ZZAP treatment, but 1 mL 
packed RBCs must be obtained. Combine packed RBCs and 
ZZAP at a 1:2 ratio, mixing well (e.g., 1 mL packed RBCs to 
2 mL ZZAP). Incubate the mixture for 30 minutes at 37°C, 
mixing periodically. After incubation, wash the RBCs at least 
three times with saline to remove the ZZAP (additional washes 
may be necessary to obtain a clear supernatant). The final wash 
is centrifuged a minimum of 5 minutes at 900–1000g to pack 
the RBCs and allow for removal of as much saline as possible.6 
This step is important, since excess residual saline may dilute 
the plasma or serum during adsorption.10 Suctioning with a 
small-bore pipette or using filter paper may be helpful.
Autologous Adsorption
Combine plasma or serum with ZZAP-treated autologous 
RBCs at a 1:1 ratio (equal volumes of both); the volume of 
ZZAP-treated autologous RBCs may be increased, however, 
to enhance antibody uptake. Incubate the mixture at 37°C for 
10–60 minutes in a water bath, mixing periodically.6,10
After incubation, centrifuge the mixture to pack the RBCs. 
Carefully remove as much adsorbed plasma or serum as 
possible without disturbing the packed RBCs. After removing 
the adsorbed plasma or serum, discard the adsorbing RBCs; 
additional autologous adsorptions should be performed using 
a fresh aliquot of ZZAP-treated autologous RBCs.6
The number of autologous adsorptions needed to remove 
the original reactivity generally correlates with the strength 
of reactivity observed with reagent panel RBCs tested by an 
indirect antiglobulin test with any test method. Generally, 1+ 
reactivity will be removed with one autologous adsorption, 
2+ reactivity removed with two autologous adsorptions, and 
so on. Additional autologous adsorptions may be necessary 
regardless of this guideline.6,7
Adsorbing more than four times should be avoided to 
prevent dilution of underlying alloantibodies.6 It is good 
practice to test the adsorbed plasma or serum after the first 
autologous adsorption (if original 1+ reactivity) or after the 
second autologous adsorption (if original 2+ reactivity) against 
group O reagent panel RBCs or direct antiglobulin test–
negative autologous RBCs to determine the need for additional 
adsorptions. If reactivity remains, perform additional 
autologous adsorptions until the extra reactivity is removed. 
Once the autoantibody is fully adsorbed, the adsorbed plasma 
or serum can then be tested against any panel RBCs to 
investigate for underlying alloantibodies. 
Limitations
Autologous adsorptions should not be performed when 
the sample to be tested consists of a mixture of transfused 
and autologous RBCs. If a patient has been transfused within 
the last 3 months, transfused RBCs may adsorb a clinically 
significant alloantibody as well as the WAA.4 Known 
transfusion history of the patient is thus of great importance.
In addition to determining the patient’s transfusion 
history, the volume of patient RBCs should be assessed. 
Patients who have a low hematocrit may not be able to provide 
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enough RBCs to perform adequate autologous adsorptions. In 
these cases, the use of allogeneic RBCs may be used in lieu of 
autologous RBCs.1
Adsorptions, whether autologous or allogeneic, can dilute 
a weak-reactive alloantibody to undetectable levels. For every 
adsorption, the dilution factor increases. It is imperative to 
completely remove saline after the final wash to reduce the risk 
of alloantibody dilution.
The use of ZZAP can have limitations. If the autoantibody 
is specific to a DTT- or enzyme-sensitive antigen, it will not be 
adsorbed out and can continue to mask alloantibodies.11
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